Children with type 2 diabetes (T2D) face a strikingly high complication rate as they become young adults, with an 80 percent incidence of at least one vascular complication, as shown in the TODAY* study.
Treatment with once-weekly subcutaneous semaglutide and once-daily insulin degludec sustained an HbA1c level of ≤7.5 percentin individuals with adequately controlled type 2 diabetes (T2D) who were on multiple daily injections of insulin (MDI) regimen, according to the TRANSITION-T2D study presented at ADA 2023.
Individuals with type 2 diabetes (T2D) may fare better with metabolic bariatric surgery, which confers more favourable long-term outcomes as compared with intensive medical and lifestyle management, based on the 7- and 12-year data from the ARMMS-T2D* trial.
Treatment with once-weekly tirzepatide, a GIP* and GLP-1** receptor agonist, led to a substantial weight reduction among overweight or obese adults with type 2 diabetes (T2D), according to the phase III SURMOUNT-2 trial presented at ADA 2023.
Putting an end to the use of metformin may lead to a higher risk of cardio-renal events in patients with diabetes and advanced chronic kidney disease (CKD), regardless of their cardiovascular disease (CVD) status, suggests a study presented at ADA 2023.
Treatment with sodium-glucose lowering co-transporter 2 inhibitors (SGLT2i) helps arrest the decline in estimated glomerular filtration rate (eGFR) and is associated with a lower risk of adverse kidney events among adults with diabetes, irrespective of baseline albuminuria status, as shown in a study presented at the recent ADA 2023.
In a subanalysis of a phase II trial on obesity, retatrutide, a triagonist of GIP*, GLP**, and glucagon receptors, also demonstrated multiple favourable signals for nonalcoholic fatty liver disease (NAFLD).